Mutagenesis-Based Active-Site Characterization of the Diabetes Drug Target MitoNEET by Mickley, Lisa
The University of Akron
IdeaExchange@UAkron
Honors Research Projects The Dr. Gary B. and Pamela S. Williams HonorsCollege
Spring 2016
Mutagenesis-Based Active-Site Characterization of
the Diabetes Drug Target MitoNEET
Lisa Mickley
lmm165@zips.uakron.edu, lmm165@zips.uakron.edu
Please take a moment to share how this work helps you through this survey. Your feedback will be
important as we plan further development of our repository.
Follow this and additional works at: http://ideaexchange.uakron.edu/honors_research_projects
Part of the Analytical Chemistry Commons, Medicinal-Pharmaceutical Chemistry Commons,
and the Other Chemistry Commons
This Honors Research Project is brought to you for free and open access by The Dr. Gary B. and Pamela S. Williams
Honors College at IdeaExchange@UAkron, the institutional repository of The University of Akron in Akron, Ohio,
USA. It has been accepted for inclusion in Honors Research Projects by an authorized administrator of
IdeaExchange@UAkron. For more information, please contact mjon@uakron.edu, uapress@uakron.edu.
Recommended Citation
Mickley, Lisa, "Mutagenesis-Based Active-Site Characterization of the Diabetes Drug Target MitoNEET" (2016).
Honors Research Projects. 278.
http://ideaexchange.uakron.edu/honors_research_projects/278
 
 
 
 
 
 
 
 
 
 
 
 
 
Mutagenesis-Based Active-Site Characterization of the Diabetes Drug Target 
MitoNEET 
 
Lisa Mickley 
Biochemistry Major (Department of Chemistry) 
Project Sponsor: Dr. Thomas C. Leeper 
Number of Credits: 4 
April 21, 2016 
  
 2 
Abstract: This project investigates the cluster stability of an outer mitochondrial membrane 
protein mitoNEET under mutational stress and drug binding analysis. MitoNEET is a part of 
a class of proteins that coordinate an Fe-S molecule into its tertiary structure. This protein is 
believed to facilitate the oxidative capacity of the electron transport chain by reversible loss 
of its coordinated Fe-S molecule. The research of this paper uses site directed protein 
mutagenesis to selectively alter the three cysteine, one histidine cluster coordination into 
more common coordination patterns such as two cysteine, two histidine or four cysteine. 
The ultimate goal is to optimize conditions for future research and analysis by UV-Vis 
spectrometry. Research led to the conclusion that optimal conditions for kinetic analysis 
under acidic conditions were in a pH 5.5 20 mM citric acid reaction buffer with 100 mM NaCl 
and 5% DMSO. To the reaction buffer 100 M protein and 100 M drug were added. This 
reaction was carried out using the Shimadzu Spectra apparatus ( = 459 nm) and the 
reaction cuvettes were temperature controlled by a water bath at 27C to yield complete 
cluster loss within 6 hours. 
 
Introduction 
MitoNEET is a 17-kDa protein containing 106 amino acid residues found on the 
outer mitochondrial membrane (OMM). It was discovered in 2004 by Colca, et. al while 
investigating the side effects of the diabetes drug pioglitazone (Colca, et al. 2004). It is 
anchored to the OMM by its amino terminus leaving its carboxy terminus oriented toward 
the cytoplasm (Wiley, Murphy, et al. 2007). As identified by Paddock, et. al in 2007 there 
are two distinct regions of the mitoNEET homodimer – the β-rich domain, which was 
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coined the β-cap, and the helical 2Fe-2S binding, or cluster binding, domain (Paddock, et al. 
2007). Its two protomers are interrelated by an unusual β strand swap that forces contacts 
between residues on opposing protomers and increases 
cooperativity (Baxter, Jennings and Onuchi 2011). According 
to research done by Baxter, et. al in 2012, the protein’s strand 
swap causes cooperative folding and assembly and results in 
dimerization preceding final folding (Baxter, Jennings and 
Onuchic 2012).  
This protein has sparked researchers’ curiosity 
through the unique coordination of its iron-sulfur cluster. Iron 
sulfur cluster containing proteins using two iron atoms and 
two sulfur atoms (Fe2S2) are most commonly found with two 
coordination patterns. The Rieske centers are characterized by a two cysteine, two 
histidine coordination. Comparatively the ferredoxin family of iron-sulfur proteins is 
characterized by a coordination complex of four cysteines. The cluster coordination in 
mitoNEET (mNT) could be considered an intermediate between the two most commonly 
known coordinations, utilizing a three cysteines and one histidine complex coordination, 
and has led to the discovery of a new class of CDGSH Fe-S domain proteins (Lin, et al. 2007) 
(Wiley, Paddock, et al. 2007). 
Figure 1: Structural 
representation of mitoNEET; 
data obtained from the Protein 
Data Bank (PDB ID 2qh7). This 
figure shows the distinctive 
features of the protein of 
interest – its strand swapping, 
β-cap, cluster binding domain, 
and cluster coordination. 
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The coordinating histidine residue has been shown to be critically important during 
redox chemistry of the protein’s iron-sulfur cluster. A simple mutation of the residue from 
His to Cys decreases the redox potential (Em) by more than 300 mV, increasing the stability 
of the cluster (Conlan, et al. 2011) (Bak and Elliot 2013). Though the mutational stresses of 
this mutation on cluster stability have been well studied, the stresses introduced by 
altering the remaining coordinating residues has yet to be determined. Therefore, testing 
the stability of the cluster 
under mutational stress 
shows investigative 
promise. Studying these 
effects requires a library of 
mNT active site mutants 
such as those listed in 
table 1. With a library such as this, comparisons can be made across each unique 
coordination pattern within mNT. Independent of mutational stress the redox potential has 
also been found to be sensitive to variation in pH with stability decreasing at pH values 
below 8 (Bak, Zuris, et al. 2009) (Zuris, et al. 2011).  
The focus of my project was to investigate the stability of mitoNEET’s iron-sulfur 
cluster in mildly acidic conditions and its rate loss over time. MitoNEET has been 
implicated as a mitochondrial Fe-S trafficking protein and understanding rate kinetics of its 
redox potential is essential to the advancement in our understanding of this diabetes drug 
target (Wiley, Murphy, et al. 2007) (Lin, et al. 2007).  Unique to many other proteins the 
iron cluster of this homodimeric protein causes mitoNEET to take on a red color in its holo-
Mutant Cluster Coordination Familiar Similarity 
WT C72, C74, C83, H87 mitoNEET (CDGSH)  
H87C C72, C74, C83, C87 ferredoxin 
C72H H72, C74, C83, H87 Rieske 
C72H, H87C H72, C74, C83, C87 mitoNEET (CDGSH) 
C74H C72, H74, C83, H87 Rieske 
C74H, H87C C72, H74, C83, C87 mitoNEET (CDGSH) 
C83H C72, C74, H83, H87 Rieske 
C83H, H87C C72, C74, H83, C87 mitoNEET (CDGSH) 
Table 1: A list of all the active site mutants and which coordination 
pattern they follow post directed mutagenesis 
llow post directed mutagenesis. 
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form. Because of this property, the loss of its iron-cluster can be monitored over the course 
of time using UV-Vis spectroscopy. As the protein begins to lose its iron to the solution, its 
color fades and the decrease in absorbance can be correlated to an increase in the 
concentration of the apo-form in solution (Lin, et al. 2007). Comparing absorbance curves 
we are able to understand relative stabilities of the mutant library. 
Another way that the stability of the cluster can be altered is by adding a drug that 
will target mNT to the reaction solution. This can be used in addition to protein 
mutagenesis to provide a broader scope to investigative results. MitoNEET was discovered 
by researchers while investigating the effects of pioglitazone that could not be explained 
via PPAR- (Geldenhuys, Leeper and Carrol 2014) (Rizos, et al. 2009). As previously 
mentioned, pioglitazone is a diabetes drug commonly used today to treat type 2 diabetes, 
along with diet and exercise. This drug is a part of the thiazolidinedione class of 
medications that work to increase the body’s sensitivity to insulin by enhancing oxidative 
capacity and normalizing lipid metabolism (Paddock, et al. 2007). Previous to the discovery 
of mNT, the mechanism by which pioglitazone enhanced oxidative capacity had yet to be 
determined. As a protein of the OMM involved in electron transfer and associated with the 
activity of complex I of the cellular respiratory chain, binding of pioglitazone to this protein 
effects oxidative capacity by stabilizing its cluster coordination and therefore decreases 
oxidative stress (Wiley, Murphy, et al. 2007) (Brunmair, et al. 2004). Since the discovery of 
mNT in 2004 via this drug, pioglitazone has been used repeatedly to study the properties of 
mNT and therefore can be a means by which to validate novel technique and results 
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obtained from such techniques. Though it has become a standard drug used to study mNT, 
its limited solubility in water of only 0.00442 mg/mL presents challenges to studying 
proteins, such as mNT, that are water soluble (Bieganski and Yarmush 2011) (Wishart, et 
al. 2006). Because of this limitation and the stabilizing effects DMSO had on cluster 
stability, we began to search for an alternative drug. Dr. Geldenhuys of NEOMED has 
recently begun to use nitrofurantoin (nF) to study mNT – a novel analysis. Nitrofurantoin 
with a water solubility of 0.415 mg/mL became an appealing alternative to pioglitazone 
(Wishart, et al. 2006). Nitrofurantoin is an antibiotic commonly used to treat urinary tract 
infections providing a reasonable 
explanation for its increased water 
solubility (American Society of Health-
System Pharmacists 2010) . Though this 
drug minimized the need for DMSO in 
solution, it did not come without its own 
set of complications. Nitrofurantoin has a 
characteristic yellow coloration which 
seemed to interfere with absorbance at 
459 nm though previous publications did not indicate this may be the case (Conklin and 
Hollifield 1965).  
 As investigations for this project evolved, the focus of the assay turned more toward 
drug analysis and away from mutational stress due to available investigative resources, not 
all mutants were successfully synthesized. This paper details the investigative process 
toward the final results and the motivations that led toward those results.  
Figure 2: This figure shows the chemical 
structure of both drug compounds. Highlighted 
in red is their structural similarity and possible 
interaction site with mNT. 
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Materials and Methods 
 Primer Design / PCR: For each of the desired mitoNEET mutants Agilent QuickChange 
primer design was used to design appropriate primers for the mutants of interest (H87C, 
C83H, C72H, C74H, H87C C83H, H87C C72H, and H87C C74H). The ExPASy ProtParam web 
tool was used on each mutant strain to evaluate the predicted effects these mutations 
would have on the molecular weight, pI, extinction coefficient, and E. coli half-life.  Finally 
primers were ordered from Integrated DNA Technologies (Coralville, IA). After primers 
arrived, PCR reactions were run in microcentrifuge tubes for each mutant of interest. To 
the tube appropriate amounts of ddH2O, reaction buffer, plasmid DNA template, sense and 
anti-sense pimers, dNTP 
mix, and PfuTurbo DNA 
polymerase were added to 
the microcentrifuge  
tube (see table 2). 
The reaction mixture was 
then thermocycled using a PCR program for appropriate amplification cycling through 
sequential temperatures of 95C, 60C, and 68C respectively. After PCR amplification, 
Cycle Step Number of Cycles Temperature ( C) Time 
Initial Denaturation 1 95 1 min 
Replication 
a) Denaturing 
b) Annealing 
c) Extension 
18  
95 
60 
68 
 
50 sec 
50 sec 
4.5 min 
Final Extension 1 68 7 min 
Hold 1 4  
Component Volume (L) Final Concentration 
Sterile H2O 36.5 NA 
10x rxn buffer 5 1x 
Template DNA 1 10 ng/L 
Sense Primer 1.25 100 ng/L 
Anti-sense Primer 1.25 100 ng/L 
dNTP mix 1  
Quick Solution 3 NA 
PfuTurbo DNA Polymerase 1  
Table 2: PCR reaction conditions. 
 
Table 3: Thermal Cycler temperature and run settings. 
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 1 L of Dpn1 restriction enzyme was added to the mixture and incubated in a 37C water 
bath for an hour.  
 
Plasmid Propagation, or Transformation of XL10-Gold Cells: Protocol was taken from 
QuickChange II XL Site-Directed Mutagenesis Kit instruction manual (Agilent Technologies 
2013). XL10-Gold ultracompetent cells were thawed on ice and 45 L aliquots were added 
to prechilled 15 mL falcon tubes. -ME mix (2 L) was added to the aliquots and contents 
were incubated on ice for 10 minutes with gentle swirling every 2 minutes. The Dpn1-
treated DNA (2 L) were then transferred into the aliquots of ultracompetent cells and heat 
pulsed in a 42C water bath for 30 seconds before a 2 minute incubation on ice. Preheated 
NZY+ broth (0.5 mL) was then added to each tube for an hour incubation at 37C with 
shaking at 225-250 rpm. Post incubation the transformation was plated onto LB-ampicillin 
agar plates and incubated at 37C overnight. 
 
DNA plasmid miniprep: A single colony was isolated from the XL10-Gold transformation 
plates to inoculate a culture of 5 mL LB-ampicillin. The culture was then incubated at 37C 
for 12-16 hours with shaking at 260 rpm. In 1.5 mL microcentrifuge tubes, bacterial cells 
were pelleted by centrifugation at room temperature and 10,000xg for 1 min. The bacterial 
pellet was then resuspended in 250 L of solution I/RNase A solution, mixed by pipetting, 
and transferred to a new 1.5 mL microcentrifuge tube. Solution II (250 L) was then added 
to the new microcentrifuge tube and gently mixed by inversion to obtain a clear lysate. 
Solution III (350 L) was added and mixed, again by inversion, to form a white flocculent 
precipitate. During a 10 minute room temperature centrifugation at 13,000xg the HiBind 
 9 
DNA Miniprep Column was prepared by adding 100 L of equilibration buffer and the 
centrifuged in a 2 mL collection tube for 1 minute at 13,000xg. Post the 10 minute 
centrifugation, the cleared supernatant was poured into the HiBind column without 
disturbing the pellet. The lysate was passed through the column by centrifugation at 
13,000xg for 1 minute and the flow through was discarded. The next step was repeated 
twice; 700 L of DNA wash buffer was added to the column and centrifuged at 13,000xg for 
1 minute. To dry the column matrix the empty column was then centrifuged at 13,000xg for 
2 minutes. The column was then placed in a clean 1.5 mL microfuge tube and 50 L of 
elution buffer was added directly onto the column matrix and centrifuged for 1 minute at 
13,000xg. Yield and quality of DNA were obtained by reading UV absorbance at 260 nm and 
280 nm.  
 
Transformation of C43 DE3 Cells: Transformation of the C43 DE3 cells was similar to that 
of the XL10-Gold but with some modifications to optimize transformation for these cells. 
Miniprepped plasmid DNA (50 ng) was added to 50 L of the thawed C43 DE3 cells on ice 
and gently stirred with a pipette tip before a 30 minute incubation. After incubation, the 
cells were heat shocked in a 42C water bath for 45 seconds. Following heat shock the cells 
were returned to ice for 2 minutes. Room temperature expression recovery medium (950 
L) was added to the solution mixture before being placed in the shaker for one hour at 
250 rpm and 37C. The transformed cells were then plated in two volumes onto ampicillin-
LB agar plates to ensure variation in colony density and incubated overnight at 37C. 
 
 10 
Protein Expression: Transformed C43 DE3 cells were used to inoculate an overnight 
culture in 25 mL of 2xYT medium. After incubation, a Fernbach flask containing 500 mL of 
the same medium was inoculated with the 25 mL overnight. Optical density at 600nm 
(OD600) was monitored and cultures were supplemented with 1 M Fe(III)Cl3 at an OD600 of 
0.2. Growth was once again monitored and temperature was decreased to 29C once an 
OD600 between 0.6 and 0.7 was obtained so as to allow the cells to adjust to the final 
induced growth temperature change before introducing them to IPTG. At an OD600 of 0.8, 
IPTG was added to a final concentration of 0.5mM to induce mitoNEET expression. After 
the addition of IPTG the culture was left to inoculate for 10 hours before being centrifuged 
at 10,000 xg for 8 minutes and pelleted. Pellets were stored overnight at 4°C. 
 
Protein Purification: Pelleted cells were resuspended in 25 mL of buffer A (50 mM Tris, 
300 mM NaCl, 20 mM imidazole; pH 8.5). Cell lysis was accomplished via French pressure 
cell, taking advantage of the cell’s inability to appropriately adjust to rapid decreases in 
pressure. Lysed cells were centrifuged for 15 min at 14,000xg and 4C. The supernatant 
was retained for further purification using immobilized metal affinity chromatography 
(IMAC). These proteins were designed to contain a 6xHis-tag that will bind nickel and can 
be utilized for purification. Columns used for the purification of these proteins were 
HisTrap (General Electric) columns and were stored in 20% v/v ethanol. Since ethanol 
solutions can denature any protein the columns had to be prepped with consecutive 
washes of water, buffer A, buffer B, and finally buffer A again. After this preparatory 
sequence the protein sample was injected into the column and washed with buffer A. With 
the His-tag, elution of the protein from the column required a gradient addition of buffer B 
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(50 mM Tris, 300 mN NaCl, 600 mM imidazole; pH 8.5) taking advantage of imidazole’s 
higher affinity for the Nickel column than a 6xHis-tag. The eluted protein was collected into 
fractional tubes and pooled for dialysis. The column was washed with water before storage 
in ethanol. The protein was then dialyzed overnight in 50 mM Tris, 300 mM NaCl pH 8.5 
with thrombin added for cleavage of the His-tag. The cleaved protein was once again run 
through the AKTA with the His-trap column however without the tag, fractions were 
collected immediately upon injection. Depending on the volume of pooled fractions, a 
concentration step using the spin column was sometimes required between AKTA runs. 
After AKTA purification the protein samples were concentrated using the spin column and 
stored at 4°C for future experimentation.  
 
Acrylamide Protein Gels: Throughout protein purification 20 L aliquots were removed 
as a means to test efficacy of purification. Post complete purification these aliquots were 
analyzed on analytical gels. Equal volume of 2xSDS-10% -mercaptoethanol loading buffer 
containing Omni-Pure Coomassie® R250 brilliant blue dye (EMD Chemicals, Gibbstown, NJ) 
was added to the 20 L aliquots and the samples were placed on the heat block at 95C for 
5 minutes. After removal from the heat block the samples were agitated via washboarding 
technique along the test tube rack before a brief centrifugation at maximum speed. The 
Bio-Rad Mini-PROTEAN® Tetra Electrophoresis system was then assembled and prepared 
using 1x Tris, Glycine, SDS running buffer and 10 L of sample were loaded into each of 15 
wells. Prestained protein ladder (5 L) was added to the remaining well and the gel was 
run at 200 V for  approximately 30 min, or until there was sufficient separation. Post run 
the gel was carefully removed and placed in a gel box, rinsed with water, and covered 
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sufficiently with blue-silver dye stain. After sufficient staining the gels were destained with 
water and viewed in the lightbox.   
 
Fe-S Stability Assays: Purified and concentrated protein mutants were tested for Fe-S 
cluster stability via two experimental techniques, both similar in methodology however 
differing in the number of conditions that can be tested in a given trial.  
Protocol 1: 96 well plate assays with a total volume of 200 L per well were used to 
compare Fe-S stability across the mitoNEET mutants. Optimal conditions for the 96 well 
plates were determined to be 13.75% DMSO, 80 M mNT in pH 5.5 Fe-S buffer (20 mM CA, 
100 mM NaCl) for pioglitazone drug analysis. Drug analysis with nitrofurantoin only 
required 2% DMSO in solution. Due to the inherent red color of the holo form of mNT’s 
homodimer, cluster loss could be monitored by UV-Vis Spectroscopy ( = 458 nm) for a 
period of 18-26 hours, depending on the mutant of interest, at ambient temperature. Data 
collected was processed and analyzed using Microsoft Excel.  
Protocol 2: The Shimadzu spectrometer was also used to measure absorbance loss of 
the mitoNEET mutants over time in a mildly acidic solution. Purified and concentrated 
protein solutions stored in buffer A were added to a Fe-S buffer (20 mM citric acid, 100 mM 
NaCl; pH 5.75) and 5% DMSO solution for cuvette analysis. Absorbance was measure at 459 
nm, the temperature was set to a standard of 27C, and the experiment was set to run on 
kinetics from between 10-18 hours depending on the mutant of interest. Post completion 
the data was collected and analyzed in Microsoft Excel.  
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Results and Discussion 
 
 Research is a collaborative effort with many individuals understanding the logistics 
of a variety of techniques however over time becoming more specialized and capable in 
specific areas. Due to the nature and focus of my project, I had limited experience with 
Primer Design, PCR, DNA miniprep, and transformation. I did have broader exposure to 
protein expression and purification; however, the majority of my experience spent in the 
laboratory was directed toward optimization of monitoring Fe-S cluster loss of mNT 
mutants in acidic solution via UV-Vis spectroscopy. These results will elaborate on my 
methodology of optimization.  
   Though the original objective for these kinetic assays was to compare relative 
stability of the cluster mutants, Table 4 shows why the focus and investigative purpose 
quickly changed. In order to successfully compare mutant stability, the mutants must be 
available. After months of research and systematically working through the synthesis of 
each mutant unfortunately, the only mutants successfully synthesized were WT, H87C, 
C83H, and C83H H87C. With this limited library from which to work it was decided that 
drug studies would be a great compliment to the available mutants. It is for this reason that 
the Mutant Expression Purification Stock Concentration (> 2mL) 
WT complete complete 1.75 mM 
H87C complete complete 0.656 mM 
C72H complete incomplete NA; colorless after AKTA 2 
C72H, H87C complete incomplete NA; colorless after AKTA 2 
C74H complete incomplete NA; colorless after AKTA 2 
C74H, H87C complete complete  
C83H complete complete 0.467 mM 
C83H, H87C complete complete 0.554 mM 
Table 4: A summary of mutant protein synthesis results.   
 
Table 2: A summary of mutant protein synthesis results.   
 14 
two drugs – pioglitazone and nitrofurantoin – became a prominent part of my research. 
Table 4 provides a general overview of the results of synthesis; however, Figure 3 can be 
utilized to compare relative purities of these four samples.  
Previous to my time spent in the lab, publications concerning mNT had indicated 
that a pH of less than 8 would destabilize the coordination of mitoNEET’s cluster; however, 
the appropriate buffer was yet to be determined (Bak, Zuris, et al. 2009) (Zuris, et al. 2011). 
Determination of optimal conditions began by testing a range of acidic pH buffers for both 
Figure 3: Analytical protein gels run for each synthesized mutant. A) C83H cleaved protein, 
concentrated flow through, uncleaved; LADDER; H87C C83H crude lysate, concentrated flow 
through, fraction 6, uncleaved B) C72H crude lysate; H87C C72H flow through, fraction 2; 
LADDER; C72H cleaved, fractions 2-4, flow through; H87C C72H crude lysate C) LADDER; 
C74H cleaved, uncleaved, flow through, fraction 7 uncleaved, crude lysate D) LADDER; H87C 
resuspended, crude lysate, flow through, fractions 2-6 uncleaved, cleaved 
A)	C83H	/	H87C,	C83H	 	 	 	 B)	H87C,	C72H	/	C72H	
	 	
C)	C74H	 	 	 	 	 	 D)	H87C	
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Tris and citric acid to determine which would be the most favorable for further studies. 
Results can be seen in Figure 4. These data show that at a pH of 5.5 in a 20 mM citric acid 
(CA) buffer with 100 mM NaCl the 2Fe-2S cluster is destabilized over a reasonable time 
scale with complete loss occurring before 400 min.  
These results gave an appropriate starting point for which to design future drug 
studies. Since pioglitazone had already been proven to significantly stabilize the 2Fe-2S 
cluster of WT mNT and was available for our use, experiments were run with pioglitazone 
to verify the accuracy and robustness of our conditions. In Figure 7 we see that in a 2:1 
Figure 4: In the kinetic assay above absorbance values ( = 458 nm) were collected every 10 min for 
18 hours. Conditions for each curve can be determined using the key to the right of the graph. 
Cluster loss of 40 M mNT occurred most effectively in the pH 5.5 20 mM CA buffer with 100 mM 
NaCl. Data Collected 10-16-2014. 
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Figure 7: In the kinetic assay above absorbance values ( = 458 nm) were collected every 2 minutes 
over the course of 18 hours. All sample conditions were run in a 20 mM CA buffer with 100 mM NaCl 
of varying pH with a standard 5% DMSO and [pioglitazone]:[mNT] ratios varying from 1:1 to 1:2. Data 
Collected 10-21-2014. 
 
Figure 6: Conditions for the above graph are 
the same as those listed in Figure 7 however 
data graphed is restricted to pH 5.5. Data 
Collected 10-21-2014. 
 
Figure 5: Conditions for the above graph are 
the same as those enumerated in Figure 7 
however data graphed is restricted to pH 5.75. 
Data Collected 10-21-2014. 
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ratio (pioglitazone:mitoNEET) the protein’s 2Fe-2S cluster is visibly stabilized. Highlighting 
specific sets of results, in Figures 5 and 6 only curves of comparable conditions are shown. 
These results seem to confirm previous studies, showing great promise as we began to 
proceed.  
 Though results were promising, reevaluating calculations and procedure it became 
apparent that the drug wells possessed a subtle DMSO gradient. To verify results were not 
from the DMSO gradient, a range of DMSO percentages were prepared and run. The results 
from the 5-25% gradient can be viewed in Figure 8, which compares the relative 
stabilization of 15%, 20%, and 25% DMSO in solution. From the graph it becomes apparent 
Figure 8: In the kinetic assay above absorbance values ( = 458 nm) were collected every 2 minutes 
over the course of 18 hours. All sample conditions were run in a pH 5.5 20 mM CA buffer with 100 
mM NaCl across a DMSO percentage gradient of 5-25%. Data Collected 10-28-2014.  
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that at 20% DMSO in solution, the stabilizing effects of DMSO begin to overshadow those of 
pioglitazone. At 10% however, pioglitazone continues to be the dominant player. These 
conclusions are drawn from the fact that pioglitazone will bind each monomer of mNT to 
stabilize its active cluster. In solution at the same concentration of protein – if all 
pioglitazone is bound to mNT – only half the protein’s potential binding sites are occupied 
and its active cluster will only be minimally stabilized. At double the concentration of mNT, 
all sites will be occupied and therefore we should see the full stabilizing effects of 
pioglitazone. At percentages of 20% or more DMSO in solution, pioglitazone in a 1:1 
concentration ratio to mNT already displays noticeable stabilization – more than we would 
expect – and 
doubling the drug 
concentration 
doesn’t seem to 
provide additional 
stabilization. To 
study the effects of 
pioglitazone 
stabilization DMSO 
percent in solution 
therefore must be 
limited to less than twenty percent. Figure 9 shows the stabilizing effect of DMSO in 
solution. This experimental trial unfortunately confirmed suspicions that in the absence of 
Figure 9: The kinetic assay above aims to demonstrate the stabilizing 
effects of DMSO in solution for 40 M mNT w/o pioglitazone. Data 
Collected 10-28-2014. 
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drug, DMSO has a stabilizing effect on the 2Fe-2S cluster of mitoNEET. In order to perform 
drug studies with pioglitazone, DMSO must be in solution to solubilize the drug; however, 
too much will give us a false positive and hinder accurate interpretation of results.  
Narrowing the percentage range to between 5% and 15% DMSO yielded similar 
results confirming the stabilizing effects of DMSO under acidic conditions (Figure 10). A 
minimum limit of 10% DMSO in solution was discovered to be necessary for complete 
dissolution of pioglitazone into the reaction solution. So as to reduce the background 
stabilization by DMSO and allow the stabilizing effects of pioglitazone to predominate, the 
working concentration for mitoNEET was doubled to yield results in Figure 11.  
Figure 10: All conditions were kept consistent from figure 7 except that the DMSO percentage range 
was narrowed to between 5% and 15%. Here we still see the stabilizing effects from before. Data 
Collected 11-11-2014. 
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 The results above led to the conclusion that optimal conditions for the assay of 
interest were at 13.75% DMSO, 80 M mNT, and room temperature run for 24 hours in the 
pH 5.5 Fe-S buffer (20 mM CA with 100 mM NaCl). Though running these experiments at 
room temperature presents a comparative roadblock when trying to explain clinical 
significance, heating the plate through the length of the assay caused evaporation and/or 
condensation effects that prevented any useful data from being obtained. Experiments 
were therefore run at ambient temperature.  
Figure 11: For the kinetic assay above the reaction was run in a pH 5.5 20 mM CA buffer with 100 mM 
NaCl for 24 hours with absorbance values ( = 458 nm) taken every 2 min. DMSO percentages in 
solution ranged from 10% to 15% and mitoNEET concentrations were increased to 80 M. Data 
Collected 11-18-2014. 
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 Concerned that the drug studies with pioglitazone and its DMSO requirements 
presented too many confounding variables, drug analysis with pioglitazone halted and 
focus was redirected toward nF, a drug with a much higher water solubility. Similar to 
pioglitazone, we notice a stabilizing effect for nF on the 2Fe-2S cluster of mNT. Results 
using the 96 well plates allowed for effective comparison of conditions during 
optimization; however, temperature control was limited and heating from the bottom of 
the plate led to significant condensation and/or evaporative effects.  Though cuvette assays 
Figure 12: This kinetic assay was run with nF (nitrofurantoin) instead of pioglitazone. Notice the 
required percentage of DMSO in solution is much lower for nF solubility. The assay above reveals 
that nF similar to pioglitazone has a stabilizing effect on the 2Fe-2S cluster of mNT. Also notice the 
spike in absorbance with the addition of nF even though its absorbance spectra is believed to fall 
outside the range of 459 nm. Nitrofurantoin concentrations were 125 M for this trial. Data collected 
4-29-2015. 
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limit the number of conditions that can be tested during an individual trial, or experiment, 
to one, the remaining data was collected in this manner due to more even temperature 
control. Results of similar conditions, therefore were compared across consecutive days. 
 In Figure 13 we see the promising results of cuvette analysis. Run under the same 
conditions WT mNT in solitude, and in the presence of both pioglitazone and nF 
respectively, will lose its cluster completely prior to 6 hours into the assay. This time scale 
is a reasonable period of measure for cluster loss. Due to the limitations on time and 
complete pioglitazone solubility in 5% DMSO at concentrations greater than 100 M Figure 
13 is not completely representative of potential results from this assay. Pioglitazone is 
Figure 13: These assays were run on consecutive days under identical conditions using the Shimadzu UV-
Vis Spectrometer. Each assay was run for 18 hours using 100 M mNT in a pH 5.5 Fe-S 20 mM CA buffer 
with 100 mM NaCl.  
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known to bind to each monomer of mNT and therefore for an accurate representation its 
Fe-S cluster stabilization should be in solution as such. It is unknown as to whether or not 
nF behaves in this way as well; however, I believe treating it in the same manner has merit. 
 
Conclusion 
 
 Though the original focus of this project may have been to compare relative cluster 
stability of mNT active site mutants in an acidic buffer, the results of protein synthesis and 
purification led the project in a different direction. Focused on optimizing conditions to 
quantify, compare, and analyze 2Fe-2S cluster loss of mNT over a reasonable time-scale, 
results are as follows. Using a water bath temperature control (27C) for cuvette analysis 
via UV-Vis spectroscopy, complete absorbance decay of WT mNT in pure solution and in 
the presence of pioglitazone and nitrofurantoin will occur within the first 6 hours or 360 
minutes of the assay. Within the cuvette both protein and drug are dissolved in a pH 5.5 Fe-
S buffer (20 mM CA with 100 mM NaCl) and 5% DMSO. Protein and drug were each present 
at a concentration of 100 M in solution.  
As a means of continuing the work I have started but unfortunately did not have the 
time to finish, cuvette assays could be run with double the drug concentration to the 
concentration of protein so as to gain further insight on the true effects of both pioglitazone 
and nitrofurantoin. 
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Appendix 
 
General Safety Considerations 
 Laboratory protective equipment and clothing were worn at all times, including 
safety glasses and latex or nitrile gloves. When necessary, a standard laboratory coat was 
also considered. Long pants and close-toed shoes were worn every day. When performing 
hazardous activities, such as operating the French pressure cell or handling carcinogens, an 
authority figure was informed. Insulated gloves were worn when handling superheated or 
super cooled glassware and reagents. All broken glassware or sharps were disposed of in 
the appropriate bins. 
Handling of Biohazardous Materials 
 When coming into contact with bacteria and cells, special care was taken to avoid 
unwanted spreading of living organisms. Pipette tips used to transfer liquid containing cell 
media were immediately disposed of into designated biohazard pipette tip boxes. Other 
containers holding such media were cleaned with dilute bleach and disposed of into the 
lab’s red biohazard waste containers. When appropriate, a Bunsen burner was kept on to 
destroy aerosolized cells in the air. 
Handling of Chemicals and Reagents 
 All material and safety data sheets (MSDS) are kept in the lab. These resources were 
consulted before use for any potentially dangerous chemicals. Most of the chemicals in the 
lab are minor skin and orifice irritants and gloves were worn at all times when handling 
them. Particularity dangerous chemicals, such as ethidium bromide – a carcinogen and 
 27 
DNA mutagen – were handled with extreme care and under supervision. Long term 
exposure to such chemicals were kept to an absolute minimum. 
Instrument Operation 
 No pieces of instrumentation were operated without clearance and proper training 
on its use by an authority figure. Instruments, such as the high-speed centrifuge and French 
pressure cell, were operated only while under authoritative supervision. 
